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Abstract
Background: Population-based input function (PBIF) may be a valid alternative to full blood sampling for quantitative PET
imaging. PBIF is typically validated by comparing its quantification results with those obtained via arterial sampling.
However, for PBIF to be employed in actual clinical research studies, its ability to faithfully capture the whole spectrum of
results must be assessed. The present study validated a PBIF for [18F]FMPEP-d2, a cannabinoid CB1 receptor radioligand, in
healthy volunteers, and also attempted to utilize PBIF to replicate three previously published clinical studies in which the
input function was acquired with arterial sampling.
Methods: The PBIF was first created and validated with data from 42 healthy volunteers. This PBIF was used to assess the
retest variability of [18F]FMPEP-d2, and then to quantify CB1 receptors in alcoholic patients (n = 18) and chronic daily
cannabis smokers (n = 29). Both groups were scanned at baseline and after 2–4 weeks of monitored drug abstinence.
Results: PBIF yielded accurate results in the 42 healthy subjects (average Logan-distribution volume (VT) was 13.363.8 mL/
cm3 for full sampling and 13.263.8 mL/cm3 for PBIF; R2 = 0.8765, p,0.0001) and test-retest results were comparable to
those obtained with full sampling (variability: 16%; intraclass correlation coefficient: 0.89). PBIF accurately replicated the
alcoholism study, showing a widespread ,20% reduction of CB1 receptors in alcoholic subjects, without significant change
after abstinence. However, a small PBIF-VT bias of 29% was unexpectedly observed in cannabis smokers. This bias led to
substantial errors, including a VT decrease in regions that had shown no downregulation in the full input function.
Simulated data showed that the original findings could only have been replicated with a PBIF bias between 26% and +4%.
Conclusions: Despite being initially well validated in healthy subjects, PBIF may misrepresent clinical protocol results and be
a source of variability between different studies and institutions.
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Introduction
Kinetic modeling for positron emission tomography (PET)
studies often requires that tracer radioactivity concentration be
measured in arterial blood. Different approaches have been tried
to avoid arterial cannulation, including image-derived input
function (IDIF) and population-based input function (PBIF). IDIF,
which theoretically allows estimation of an individualized, non-
invasive input function, measures blood tracer concentration
directly from dynamic images using an anatomical blood pool,
such as the heart. However, in practice, IDIF is plagued by many
shortcomings. For instance, limited spatial and temporal resolution
of PET cameras makes reliable estimation of radioactivity
concentration in the vessels and its rapid variations over time
difficult; in addition, PET cameras cannot distinguish the parent
compound from its radiometabolites [1]. Moreover, IDIF can
yield very biased results, depending on whether partial volume and
spill-over effects are properly corrected [2,3]. These limitations are
amplified when IDIF is calculated from small vessels, such as the
carotid arteries for brain studies, but are sometimes apparent even
with larger blood pools [4].
PBIF modeling is based on the individual scaling of a tracer-
specific input function of standard shape, and may be a more
reliable alternative than IDIF. PBIF is not affected by problems
linked to image quality and resolution, and radiometabolite
correction can be inherently taken into account by using an
average time-activity curve of parent concentrations. Moreover,
because PBIF is derived from averaged values over a population, it
generally shows little or no systematic error, as estimation errors of
individual input functions would be normally distributed around
the mean. While this may pose a problem in personalized
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diagnostic settings, research studies typically compare population
means; thus, a larger standard deviation may be acceptable if
properly accounted for.
Historically, PBIF was validated primarily for [18F]-FDG
[5,6,7,8,9,10,11,12], but recent studies showed excellent results
with a wider array of tracers [13,14,15,16,17,18,19,20,21]. To our
knowledge, only one reported negative results with PBIF [22].
Although publication bias is probably partly responsible, this also
suggests that PBIF is a reliable technique. In the extant literature,
however, PBIF is typically validated as a proof of concept method
by comparing its quantification results with those obtained via
arterial sampling in a group of subjects, often comprising both
healthy volunteers and patients [5,6,7,8,12,13,14,15,16,18,19].
For PBIF to be used in research protocols, the validation
procedure must be extended to assess its ability to faithfully
capture the entire spectrum of results in complex clinical studies,
often involving patients with different conditions.
Our laboratory developed [18F]FMPEP-d2, a radioligand tar-
geting cannabinoid CB1 receptors [23]. [
18F]FMPEP-d2 concen-
trations can be accurately measured in plasma, and this allows
accurate estimation of brain distribution volume (VT) [24]. In
previous studies, we assessed inter-subject and retest variability of
[18F]FMPEP-d2 VT values in healthy volunteers [24] and
conducted two clinical studies to investigate the concentration of
brain CB1 receptors in the brain of alcoholic subjects [25] and
cannabis smokers [26]. The present study validated PBIF in
healthy volunteers and also attempted to employ PBIF to replicate
results from our previously published clinical studies that utilized
serial arterial sampling to obtain input function.
Subjects and Methods
Data from three previous publications involving imaging of
cannabinoid CB1 receptors were re-analyzed. The first study
(retest study) involved 8 healthy subjects (5 men and 3 women)
who underwent a test-retest scan [24]. The second study (alcohol
study) assessed CB1 receptors in 18 male patients with alcohol
dependence [25]; subjects were monitored in an inpatient research
unit for 2–4 weeks and CB1 receptors were imaged with PET and
[18F]FMPEP-d2 at two time points: within 1 week of admission,
and again after 2–4 weeks of abstinence. The third study (cannabis
study) assessed CB1 receptors alteration in 30 males who were
daily chronic cannabis smokers [26]; subjects were imaged within
one day of admission onto a controlled unit, and again after 2–4
weeks of abstinence. Recruitment processes and eligibility criteria
for both healthy subjects and patients are described in the original
publications [24,25,26].
Positron Emission Tomography and Measurement of
Parent Radioligand in Arterial Plasma
Radioactivity was measured in brain with an Advance PET
camera (GE Healthcare, Milwaukee, WI) over 120 minutes. The
input function was measured from radial artery plasma sampling.
Arterial samples were drawn at 15 seconds intervals until 2
minutes, and then at increasingly longer intervals until the end of
the scan, as previously described [24,25,26]. Plasma time-activity
curve was corrected for the fraction of unchanged radioligand by
radio-high-performance liquid chromatography separation [27].
PET images were analyzed by applying a template of volumes of
interest [28] as implemented in PMOD, version 3.0 (PMOD
Technologies Ltd, Zurich, Switzerland) in the standard stereotac-
tic space [29].
Generation of the PBIF
To generate the PBIF, [18F]FMPEP-d2 input functions from all
healthy subjects in our database were used. This comprised all
healthy subjects in the three previous publications described above
[24,25,26], as well as additional subjects recruited through July
2012. In total, data from 42 healthy subjects were available
(34610 years, 83618 Kg, 18169 MBq of injected activity). The
National Institutes of Health (NIH) Central Nervous System
Institutional Review Board approved the protocols and consent
forms. Written informed consent was obtained from all subjects.
The PBIF generation process includes several steps, as described
in previous publications [5,20]: 1) each parent time-activity curve
was normalized by injected activity and body weight, 2) the curves
were shifted for time delay to match the average time peak, 3) each
curve was fitted with a linear interpolation to the peak, followed by
a tri-exponential function after the peak 4) the blood values were
interpolated to the same grid of standard times (to eliminate the
errors due to slightly different sampling times), 5) the normalized
parent time-activity curves of all healthy subjects were averaged to
obtain the final PBIF, 6) for each individual subject, the PBIF was
finally individually scaled using a combination of two arterial
blood samples taken at 15 and 60 minutes. This combination was
selected because it yielded the highest correlation coefficient–as
assessed by Pearson’s analysis–between parent activity and the
total area under the curve (AUC) (Table S1).
The PBIF was first tested among healthy volunteers with a leave-
one-out procedure, i.e. when testing the PBIF on a given subject,
the input function of that subject was removed from the mean
PBIF to avoid any bias [30]. Similarly, in the test-retest study, each
retest PBIF did not include the input function from the test study
of the same subject. The PBIF from all healthy subjects was then
prospectively applied to the populations of alcoholics and cannabis
smokers, in both test and retest scans.
Analysis of VT Data
In the original studies, kinetic modeling was performed with an
unconstrained two-tissue compartmental model (2TCM)
[24,25,26]. However, in the present work we first reanalyzed the
previous studies using a Logan plot and the full arterial input
function. To test the consistency and validity of Logan-derived
results, the same statistical analyses used in the original studies
with 2TCM were repeated with the Logan plot. As shown in
Results, Logan-derived results were equivalent to those obtained
using a 2TCM and were utilized as the reference standard to
evaluate PBIF.
Statistics
Statistical analyses were performed with SPSS Statistics 17.0 for
Windows (Release 17.0.0, copyright SPSS Inc., 1993–2007).
Retest variability (the absolute difference between the two scans
divided by the mean of the two scans) and intraclass correlation
coefficients (ICC) were calculated for VT values obtained with
PBIF and compared with the values obtained with the reference
input function. Values of ICC were obtained by (BSMSS –
WSMSS)/(BSMSS+WSMSS), where BSMSS=mean of summed
squares between subjects, and WSMSS=mean of summed
squares within subjects.
We sought to replicate our previous findings of region-specific
and reversible downregulation of CB1 receptors in cannabis
smokers [26], and widespread and irreversible downregulation of
CB1 receptors in patients with alcohol dependence [25]. Down-
regulation at baseline was examined separately in both patient
groups by applying mixed model two-way analyses of variance
(ANOVA), with group status (cannabis smokers vs. control, or
Population-Based Input Function for [18F]FMPEP-d2
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alcohol dependence vs. control) as a between-subjects factor and
brain region as a within-subjects factor. Body mass index (BMI)
entered the model as a covariate [26]. To test whether CB1
receptors were increased after abstinence, we applied a two-way
ANOVA with time point (early vs. protracted abstinence) and
brain region as within-subject factors. P-values smaller than 0.05
were considered statistically significant.
Results
Validation of PBIF in Healthy Subjects and Retest Results
Visually, PBIF curves were of very good quality (Fig. 1). The
slope of the tails was very similar among the different subjects,
including the transition part between the peaks and the tail. As
expected, the height of the peaks showed a higher variability, with
errors normally distributed around a mean value (average
estimated/reference peak value: 1.0060.21). The thickness of
the peaks was also very similar among subjects. Kinetic modeling
showed that the Logan-VT (mean of all regions) in the 42 healthy
subjects was 13.363.8 mL/cm3 for Logan blood and
13.263.8 mL/cm3 for Logan PBIF (VT ratio = 1.0060.12). The
correlation between the two VT estimates was good (R
2= 0.8765,
p,0.0001). Most individual subjects showed small VT estimation
errors (,10%).
In the original test-retest study done with 2TCM, the retest
variability was 14% and the ICC value was 0.89 [24]. When the
Logan plot and the full input function were employed in the
present study, retest variability was slightly higher (16%), although
the ICC value was similar (0.88). This slightly lower mean 2TCM
retest variability appeared to be due to lower variability in
subcortical regions, such as the pons and the white matter; cortical
regions, which are more relevant for CB1 analysis, displayed
similar values (Table 1).
Alcohol Study
In the alcohol study, the Logan full input model showed
a widespread decrease in VT of [
18F]FMPEP-d2 among patients
with alcohol dependence compared with healthy subjects (main
effect of group: F= 9.06, p = 0.005) that, although found in all
brain regions, varied in magnitude across regions (group6region
interaction: F = 6.42, p = 0.002). This change was similar in
magnitude to that observed with compartment modeling in the
original study [25]. After 2–4 weeks of abstinence, Logan-VT did
not change from baseline in any region (main effect of repetition:
F = 0.69, p = 0.417; repetition6region interaction: F = 1.08,
p = 0.362), and percent change was similar to that observed with
the compartment model [25].
In the present study, PBIF accurately estimated VT values
among alcoholic subjects. The Logan-VT was 9.462.6 mL/cm
3
for Logan blood and 9.562.6 mL/cm3 for Logan PBIF (VT
ratio = 1.0260.14; R2= 0.7774, p,0.0001). PBIF accurately
replicated the widespread decrease in VT in alcoholic subjects
both in terms of magnitude and statistical significance of change
(main effect of group: F= 8.99, p = 0.005; group6region in-
teraction: F= 8.32, p = 0.0002) (Fig. 2A). After abstinence, PBIF
modeling showed a similar lack of change in VT (main effect of
repetition: F = 1.86, p = 0.191; repetition6region interaction:
F = 1.27, p= 0.294) (Table 2).
Cannabis Study
The Logan model with full arterial input function obtained
results similar to those found with 2TCM [26]. A regionally
specific decrease in VT of [
18F]FMPEP-d2 was found in cannabis
smokers compared with healthy subjects (group6region interac-
Figure 1. Comparison between the PBIF from healthy volun-
teers and the average curves in alcoholic subjects and
cannabis smokers. Average PBIF, expressed in SUV, from healthy
subjects (A). Error bars show standard deviations for each time point.
Only the first 5 minutes are shown. After 5 minutes, all curves are
virtually identical. In panel B, the black curve, with SD, represents the
average input function from alcoholic subjects and the superposed red
curve is the PBIF from healthy subjects. The two average population
curves are very similar in shape and magnitude. However, when
compared to the average curve from cannabis smokers (in black, panel
C), it can be clearly seen that PBIF (in red) overestimates the peak. This
will translate into a selective underestimation of Logan-VT in the
cannabis population.
doi:10.1371/journal.pone.0060231.g001
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tion: F = 10.0, p = 0.00004). Compared to the original paper
which included 30 cannabis smokers [26], one was removed from
the analysis because the Logan plot did not provide a correct
linearization. As with 2TCM, VT was about 20% lower in
neocortical and limbic regions, but not in other brain regions (such
as cerebellum and basal ganglia) [26]. After about 4 weeks
sustained cannabis abstinence, VT increased specifically in those
brain regions that had shown decreased VT at baseline
(repetition6region interaction: F = 4.58, p = 0.006).
The Logan-VT obtained with PBIF showed however a small bias
of about29% as compared to the Logan-VT obtained with the full
input function (12.763.4 mL/cm3 for Logan blood and
11.563.1 mL/cm3 for Logan PBIF; VT ratio = 0.9160.13;
R2= 0.7057, p,0.0001) (Fig. 1). Because of this bias, PBIF
modeling found a larger decrease in VT in cannabis smokers
(227% in the prefrontal cortex compared with 219% using full
input), and the group6region interaction was statistically highly
significant (F= 17.1, p= 0.00000001) (Fig. 2B). However, VT was
also decreased in regions that had shown no downregulation at
baseline with the full input function, namely, caudate, putamen,
ventral striatum, cerebellum, and white matter (Fig. 3). After
abstinence, PBIF modeling showed similarly significant region-
specific changes (repetition6region interaction: F= 4.96,
p = 0.011), although percent change was higher than that obtained
with the Logan full input model. Notably, PBIF-VT recovered after
abstinence only in neocortical and limbic brain regions, because
other regions (such as white matter) showed no physiological
change between baseline and abstinence conditions.
Because the bias of 29% was sufficient to cause substantial
errors in the interpretation of the regional data from the cannabis
study, we created datasets with different degrees of simulated bias
(1 percent unit increments from28% to +9%) to find the tolerable
range of bias that would allow the exact replication of the results.
In practice, starting from the actual PBIF-VT values, we created
simulated sets of VT values whose means equal the target bias and
the coefficient of variation is constant and equal to that of the real
PBIF-VT values. The simulated data showed that significant
deviations from the original findings of the study appeared with
a bias lower than26% or higher than +4%. Negative bias resulted
in false positive findings in a number of brain regions. With a26%
Table 1. Retest variability for 2TCM, Logan with full input, and Logan with PBIF, respectively.
2TCM full input Logan full input Logan PBIF
Region Retest Variability (%) ICC Retest Variability (%) ICC Retest Variability (%) ICC
Prefrontal 16 0.91 17 0.89 14 0.89
Occipital 13 0.90 15 0.90 17 0.89
Hippocampus 15 0.86 18 0.85 14 0.88
Putamen 17 0.88 18 0.87 17 0.86
Thalamus 15 0.89 17 0.87 17 0.90
Cerebellum 15 0.85 15 0.86 14 0.88
Pons 9 0.94 13 0.93 17 0.92
White Matter 11 0.88 16 0.87 17 0.89
In the present study, results with Logan and the PBIF (variability: 16%; ICC= 0.89) were nearly identical to those obtained with Logan and the full input function. VT
values obtained with 2TCM, Logan with full input and Logan with PBIF were strongly correlated (scatter plots are shown in Figure S1).
doi:10.1371/journal.pone.0060231.t001
Figure 2. Comparison of Logan-VT results in cortical and subcortical regions for healthy volunteers, alcoholic subjects and cannabis
smokers, obtained with full input and the PBIF. Results at baseline in alcoholic subjects (A) and cannabis smokers (B), compared to healthy
controls for both full input and PBIF. PBIF provided accurate Logan-VT values in healthy subjects and alcoholic patients and closely replicated
previous findings of widespread downregulation. In cannabis smokers, PBIF underestimated Logan-VT (arrows); the results suggest the erroneous
conclusion that downregulation also occurred in subcortical regions.
doi:10.1371/journal.pone.0060231.g002
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bias, basal ganglia (caudate and ventral striatum) appeared to be
significantly downregulated, a finding that is inconsistent not only
with our previous kinetic modeling study [26], but also with
animal studies showing resistance of basal ganglia CB1 receptors to
chronic agonist-induced downregulation [31]. Conversely, positive
bias reduced statistical power and caused false negative findings.
For example, a bias of +4% was sufficient to cause lack of
significant downregulation in 6 out of 10 cortical and limbic brain
regions, despite the fact that downregulation was found in all
regions with full arterial input modeling. Notably, if the 29%
PBIF VT bias would have occurred in the other direction (i.e.
+9%), the decrease would not have been statistically significant in
any of the individual brain regions (although the study still would
have demonstrated a decrease in VT -group6region interaction:
F = 4.17, p = 0.014); furthermore, no significant recovery of
receptor downregulation after abstinence would have been
observed (repetition6region interaction: F= 2.16, p = 0.097).
Discussion
This study assessed whether PBIF can reliably replicate actual
clinical protocols by comparing PBIF results to those obtained
with a full input function.
Before analyzing PBIF data, we first replicated the previous
studies using a Logan plot and the full arterial input function. This
was necessary to have data that were directly comparable to those
acquired using the Logan plot and the PBIF. In fact, compart-
mental modeling is not well suited to PBIF, because VT is derived
by combining individual rate constants, which are sensitive to the
shape of the input function. PBIF cannot accurately reproduce the
shape of the individual input functions, especially during the early
rapid phase. In contrast, the Logan graphical plot relies on the
AUC of the input function [32], which can be correctly estimated
even with a differently shaped curve. Consequently, Logan is
preferable to compartmental modeling when less invasive methods
are used to obtain the arterial input function (e.g., PBIF or IDIF).
As expected, Logan-derived results were equivalent to those
obtained using a 2TCM and were utilized as the reference
standard to evaluate PBIF.
In a large number of healthy subjects, both at baseline and in
a test-retest setting, PBIF for [18F]FMPEP-d2 gave reliable results.
Moreover, the PBIF obtained from healthy subjects also closely
replicated results from the alcohol study, showing a widespread
decrease in VT in patients with alcohol dependence, both in terms
of magnitude and statistical significance of change. After 2–4
weeks of abstinence, kinetic modeling with both full input and
PBIF showed a similar persistent downregulation of CB1 receptors.
However, despite these initial good results, PBIF-derived results
in cannabis smokers had an unexpected small bias of about 29%,
and therefore differed in some important ways from the reference
values. Had PBIF been used exclusively, we would not have missed
the main finding of the study, i.e. that cannabis smoking is
Table 2. Results from the alcohol and cannabis studies using PBIF.
Full input
(2TCM and Logan)
PBIF
(Logan)
Cannabis baseline Regionally selective downregulation Overestimation of downregulation,
non-regionally selective
Cannabis abstinence Regionally selective increase Regionally selective increase
Alcohol baseline Widespread downregulation Widespread downregulation
Alcohol abstinence No change No change
Bold text underscores differences between PBIF and full sampling modeling.
doi:10.1371/journal.pone.0060231.t002
Figure 3. Regional percent differences in [18F]FMPEP-d2 VT between healthy subjects and chronic cannabis smokers. VT values are
estimated by the Logan method with full arterial input curve (gray bars) and with PBIF (black bars). Compared with full arterial input modeling, PBIF
underestimated VT by about 9% in the cannabis group and erroneously showed statistically significant downregulation in subcortical regions that did
not differ in either compartmental kinetic modeling or Logan full arterial input modeling (asterisks).
doi:10.1371/journal.pone.0060231.g003
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associated with a downregulation of CB1 receptors in the brain
that is reversible after abstinence. However, we would have
incorrectly concluded that receptor downregulation occurred in all
brain regions non-selectively, which is inconsistent with the known
physiology of CB1 receptors [26] [31]. Notably, after abstinence
PBIF-VT recovered only in neocortical and limbic brain regions,
because other regions (such as white matter) showed no
physiological change between baseline and abstinence conditions.
This further supports the hypothesis that the downregulation seen
at baseline in those regions with PBIF was erroneous.
Simulated data showed that the range of bias that would have
allowed us to substantially replicate the original findings of the
cannabis study was between 26% and +4%. This quite narrow
margin of error is obviously specific to this population and this
study. Nevertheless, it is important to underscore that, for any new
study, it cannot be known beforehand what an acceptable bias
would be. Notably, small biases of about 10%–even at initial
validation–are not uncommon with PBIF [7,19].
With PBIF, estimated errors of VT are supposed to be normally
distributed around the mean. However, out of 29 cannabis
smokers, 27 showed underestimated VT values. Therefore, the bias
was not due to some individual outlying values, but to a systematic
difference uniform throughout the group. The mechanistic
explanation of this VT underestimation is a slightly different shape
in the input function of cannabis smokers (Fig. 1). Indeed, the
arterial input functions of cannabis smokers, although they are not
statistically separable with a t-test, have a lower peak compared to
both healthy subjects and alcoholics (Table 3). The AUC,
expressed in SUV, of the first 5 minutes (AUC0–5) in cannabis
smokers was 33.4, while it was 38.1 in healthy controls and 40.5 in
alcoholic subjects. The rest of the input function (AUC5–120) was
very similar among the three groups (32.6, 32.7 and 32.2,
respectively). Indeed, the blood sample values of cannabis subjects
used for scaling the PBIF (0.7960.19 SUV at 15 minutes and
0.1560.04 SUV at 60 minutes) were similar to those of healthy
subjects (0.7560.23 SUV and 0.1560.06 SUV, respectively).
We have no clear explanation for the blunted peak observed in
the cannabis subjects. All groups underwent the same procedure
with regard to radioligand preparation and measurement, and
were injected with an automated pump over the same time span of
one minute, which ensures a reproducible shape of the injected
bolus. Fifteen second-sampling was used during the first two
minutes to sample the input function. A continuous blood
sampling device may allow a better definition of the shape of the
peaks and should preferably be used for future studies. However
that would be an unlikely explanation for our findings, because all
input functions were acquired with the same time frame. Cannabis
smokers had a lower BMI (2464 vs. 2765 kg/m2), more tobacco
use, and higher alcohol consumption [26] (which should not have
significantly contributed to the bias, given that we accurately
replicated the study in alcoholic subjects). Hypothetical gender-
related differences are unlikely to be the cause, because 86 of the
89 subjects in the present study were males. Also, the fraction of
free radioligand in plasma of cannabis smokers (0.4260.2%) was
similar to that of healthy controls (0.4060.2%) [26]. Notably,
cannabis smokers do not display a different metabolism rate of the
radiotracer, since the AUC of the tail of the input function is very
similar to that of normal subjects and alcoholics (and very little
metabolism occurs in the first five minutes after injection). One
speculative explanation is that cannabis smokers may have
a slightly slower metabolism than healthy subjects, which would
explain a parent concentration at late time-points similar to that of
the other groups, despite an initial lower peak.
However, independent of the underlying pathophysiological
reason in this specific case, the message of this paper is that PBIF
can be very sensitive to quantitatively minor and unforeseeable
differences that may occur when transposing a given PBIF to
different populations of subjects. Moreover, all populations studied
in the present work were composed of age-matched, young
persons, free of organic disease. It is conceivable that bias
estimations found between comparable groups of healthy individ-
uals would be amplified if one group was composed of patients
with systemic, cardiovascular or neoplastic diseases.
It is certainly conceivable that better results would have been
obtained by using different PBIFs derived from each population
(indeed, a PBIF from the cannabis smokers of the present study
predictably shows a lower peak than the PBIF from healthy
subjects). However, this approach would be unfeasible in clinical
practice, because a PBIF for each specific population of patients to
be studied is usually not available. Moreover, even a PBIF derived
from a specific group of patients may not be prospectively
applicable to patients with a different degree of disease.
A 1994 study by Takikawa and colleagues provides a rare
example where the performance of PBIF was tested against the full
input in both healthy subjects and patients, and results were
correlated with clinical findings [15]. Although an [18F]-DOPA
PBIF still correctly discriminated between healthy subjects and
patients with Parkinson’s disease, it predicted quantitative severity
ratings less accurately. Striatal Ki correlated significantly with the
Unified Parkinson’s Disease Rating Score using the reference
input function, but this correlation was lost when PBIF was
employed.
In summary, care should be taken when using alternative
techniques to measure input function. Despite initially good
validation in healthy subjects, errors may unexpectedly arise in
actual clinical protocols. These errors, in turn, may lead to
a misinterpretation of results and be a source of variability between
different studies and institutions. Indeed, these erroneous results
may have important consequences for understanding basic
pathophysiology or pharmacological effectiveness of drugs. Dis-
crepant results are unfortunately not rare in molecular imaging
studies [33,34]. While clinical variability is surely partly re-
sponsible, methodological issues–including the choice of input
function–are likely to play an important role [34,35]. Therefore,
whenever possible, the input function should be obtained with the
gold standard of serial arterial sampling with individual correction
for radiometabolites.
Supporting Information
Figure S1 Scatter plots of 2TCM/Logan with full input,
2TCM/Logan with PBIF and Logan with full input/
Logan with PBIF. Values for the test scans are reported in the
left column and those of the retest scans in right column. For each
one of the test-retest subjects, a single VT value (whole-brain
Table 3. Areas under the curve, expressed in SUV, of the peak
area (first 5 minutes) and the rest of the arterial input function
in the three populations of subjects.
Healthy (n=42) Alcohol (n=18) Cannabis (n=29)
AUC0–5 38.169.6 40.569.0 33.4612.4
AUC5–120 32.769.9 32.267.5 32.666.9
AUCTOTAL 70.8618.5 72.7615.4 66.0616.1
doi:10.1371/journal.pone.0060231.t003
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region) has been used. A strong correlation exists between all
datasets.
(EPS)
Table S1 Correlation coefficients for the area-under-
the-curve of the plasma time-activity curve (AUC) using
the measured radioligand concentrations.
(DOCX)
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